{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:38:42Z","timestamp":1787009922350,"version":"build-2736575974"},"reference-count":61,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>The present review will focus on the current management of patients with chronic myelomonocytic leukemia (CMML) as well as in future therapeutic perspectives.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>\n                      CMML is a clonal hematopoietic stem cell disorder characterized by peripheral blood monocytosis and myelodysplastic and myeloproliferative alterations in the bone marrow. Clinical behavior of the disease can be heterogeneous, with some patients having an indolent form of the disease, whereas others experience an aggressive course with decreased survival and eventual transformation to leukemia. Multiple studies have helped define the clinical, cytogenetic and mutational prognostic features of the disease. In addition, several prognostic scoring systems have been developed for patients with CMML. Incorporation of mutation data, particularly presence of frameshift and nonsense\n                      <jats:italic toggle=\"yes\">ASXL1<\/jats:italic>\n                      mutations, into these models seems to be allowing to further improve our ability to predict patient outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Prognosis of patients with CMML is heterogeneous. Incorporation of mutational data into current clinical prognostic models has allowed to improve our ability to predict patient outcomes. Allogeneic stem cell transplantation remains the only potentially curative treatment for patients with CMML but is only an option for a subset of patients. For this reason, hypomethylating agents such as 5-azacitidine and decitabine have become the backbone of current therapy for patients with CMML, but new therapeutic strategies are required to improve their outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/cco.0000000000000337","type":"journal-article","created":{"date-parts":[[2016,11,15]],"date-time":"2016-11-15T09:35:01Z","timestamp":1479202501000},"page":"79-87","source":"Crossref","is-referenced-by-count":9,"title":["Current management of patients with chronic myelomonocytic leukemia"],"prefix":"10.1097","volume":"29","author":[{"given":"Ana","family":"Alfonso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Montalban-Bravo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Garcia-Manero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230901","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"R2-20230901","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"R3-20230901","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1158\/1078-0432.CCR-09-2112","article-title":"RAS mutations contribute to evolution of chronic myelomonocytic leukemia to the proliferative variant","volume":"16","author":"Ricci","year":"2010","journal-title":"Clin Cancer Res"},{"key":"R4-20230901","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.leukres.2014.09.003","article-title":"Refined medullary blast and white blood cell count based classification of chronic myelomonocytic leukemias","volume":"38","author":"Schuler","year":"2014","journal-title":"Leuk Res"},{"key":"R5-20230901","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/j.1365-2141.1994.tb06734.x","article-title":"The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French\u2013American\u2013British Cooperative Leukaemia Group","volume":"87","author":"Bennett","year":"1994","journal-title":"Br J Haematol"},{"key":"R6-20230901","doi-asserted-by":"crossref","first-page":"e95","DOI":"10.3324\/haematol.2013.084061","article-title":"Population-based incidence of myeloid malignancies: fifteen years of epidemiological data in the province of Girona, Spain","volume":"98","author":"Osca-Gelis","year":"2013","journal-title":"Haematologica"},{"key":"R7-20230901","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2008-01-134858","article-title":"Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001\u20132004, using data from the NAACCR and SEER programs","volume":"112","author":"Rollison","year":"2008","journal-title":"Blood"},{"key":"R8-20230901","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.3324\/haematol.2014.114660","article-title":"An International MDS\/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic\/myeloproliferative neoplasms","volume":"100","author":"Mughal","year":"2015","journal-title":"Haematologica"},{"key":"R9-20230901","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/ejh.12679","article-title":"Response to erythropoietic-stimulating agents in patients with chronic myelomonocytic leukemia","volume":"97","author":"Xicoy","year":"2016","journal-title":"Eur J Haematol"},{"key":"R10-20230901","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/bjh.14061","article-title":"Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic\/myeloproliferative neoplasms in the United States, 2001\u201312","volume":"174","author":"Srour","year":"2016","journal-title":"Br J Haematol"},{"key":"R11-20230901","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1002\/ajh.23751","article-title":"Cytogenetic risk stratification of 417 patients with chronic myelomonocytic leukemia from a single institution","volume":"89","author":"Tang","year":"2014","journal-title":"Am J Hematol"},{"key":"R12-20230901","doi-asserted-by":"crossref","first-page":"375","DOI":"10.3324\/haematol.2010.030957","article-title":"Cytogenetic risk stratification in chronic myelomonocytic leukemia","volume":"96","author":"Such","year":"2011","journal-title":"Haematologica"},{"key":"R13-20230901","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1200\/JCO.2012.47.3314","article-title":"Prognostic score including gene mutations in chronic myelomonocytic leukemia","volume":"31","author":"Itzykson","year":"2013","journal-title":"J Clin Oncol"},{"key":"R14-20230901","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1038\/leu.2014.125","article-title":"ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: a two-center study of 466 patients","volume":"28","author":"Patnaik","year":"2014","journal-title":"Leukemia"},{"key":"R15-20230901","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","article-title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes","volume":"122","author":"Papaemmanuil","year":"2013","journal-title":"Blood"},{"key":"R16-20230901","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1038\/leu.2013.88","article-title":"Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes","volume":"27","author":"Patnaik","year":"2013","journal-title":"Leukemia"},{"key":"R17-20230901","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood.V99.3.840","article-title":"Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients","volume":"99","author":"Onida","year":"2002","journal-title":"Blood"},{"key":"R18-20230901","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1002\/ajh.23846","article-title":"Molecular and prognostic correlates of cytogenetic abnormalities in chronic myelomonocytic leukemia: a Mayo Clinic-French Consortium Study","volume":"89","author":"Wassie","year":"2014","journal-title":"Am J Hematol"},{"key":"R19-20230901","doi-asserted-by":"crossref","first-page":"e385","DOI":"10.1038\/bcj.2015.113","article-title":"Prognostic interaction between ASXL1 and TET2 mutations in chronic myelomonocytic leukemia","volume":"6","author":"Patnaik","year":"2016","journal-title":"Blood Cancer J"},{"key":"R20-20230901","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/j.clml.2016.04.018","article-title":"Clinical prognostic factors and survival outcome of chronic myelomonocytic leukemia: reviewing 3,686 patients","volume":"16","author":"El-Fattah","year":"2016","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R21-20230901","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1182\/blood-2013-03-491399","article-title":"Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia","volume":"122","author":"Takahashi","year":"2013","journal-title":"Blood"},{"key":"R22-20230901","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1002\/ajh.23962","article-title":"Blast transformation in chronic myelomonocytic leukemia: risk factors, genetic features, survival, and treatment outcome","volume":"90","author":"Patnaik","year":"2015","journal-title":"Am J Hematol"},{"key":"R23-20230901","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1016\/j.clml.2014.06.007","article-title":"Monosomal karyotype predicts adverse prognosis in patients diagnosed with chronic myelomonocytic leukemia: a single-institution experience","volume":"15","author":"Alsahlawi","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R24-20230901","doi-asserted-by":"crossref","first-page":"e393","DOI":"10.1038\/bcj.2016.5","article-title":"Cytogenetic and molecular abnormalities in chronic myelomonocytic leukemia","volume":"6","author":"Patnaik","year":"2016","journal-title":"Blood Cancer J"},{"key":"R25-20230901","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/leu.2013.336","article-title":"Landscape of genetic lesions in 944 patients with myelodysplastic syndromes","volume":"28","author":"Haferlach","year":"2014","journal-title":"Leukemia"},{"key":"R26-20230901","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/leu.2015.337","article-title":"Age-related mutations and chronic myelomonocytic leukemia","volume":"30","author":"Mason","year":"2016","journal-title":"Leukemia"},{"key":"R27-20230901","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40164-015-0009-y","article-title":"Impact of TET2, SRSF2, ASXL1 and SETBP1 mutations on survival of patients with chronic myelomonocytic leukemia","volume":"4","author":"Cui","year":"2015","journal-title":"Exp Hematol Oncol"},{"key":"R28-20230901","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1038\/leu.2013.97","article-title":"SETBP1 mutations in 415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: independent prognostic impact in CMML","volume":"27","author":"Laborde","year":"2013","journal-title":"Leukemia"},{"key":"R29-20230901","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1002\/ajh.23702","article-title":"Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemia","volume":"89","author":"Cervera","year":"2014","journal-title":"Am J Hematol"},{"key":"R30-20230901","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1182\/blood-2002-01-0330","article-title":"New prognostic parameters for chronic myelomonocytic leukemia","volume":"100","author":"Germing","year":"2002","journal-title":"Blood"},{"key":"R31-20230901","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1002\/cncr.23697","article-title":"Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System","volume":"113","author":"Kantarjian","year":"2008","journal-title":"Cancer"},{"key":"R32-20230901","doi-asserted-by":"crossref","first-page":"3005","DOI":"10.1182\/blood-2012-08-452938","article-title":"Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia","volume":"121","author":"Such","year":"2013","journal-title":"Blood"},{"key":"R33-20230901","doi-asserted-by":"crossref","first-page":"e333","DOI":"10.1038\/bcj.2015.53","article-title":"An international data set for CMML validates prognostic scoring systems and demonstrates a need for novel prognostication strategies","volume":"5","author":"Padron","year":"2015","journal-title":"Blood Cancer J"},{"key":"R34-20230901","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1182\/blood.V88.7.2480.bloodjournal8872480","article-title":"A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Francais des Myelodysplasies and European CMML Group","volume":"88","author":"Wattel","year":"1996","journal-title":"Blood"},{"key":"R35-20230901","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/j.1365-2141.1989.tb07735.x","article-title":"Treatment of chronic myelomonocytic leukemia with low dose etoposide","volume":"72","author":"Oscier","year":"1989","journal-title":"Br J Haematol"},{"key":"R36-20230901","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/j.1365-2141.1992.tb06429.x","article-title":"Low-dose etoposide: a potential therapy for myelodysplastic syndromes","volume":"82","author":"Ogata","year":"1992","journal-title":"Br J Haematol"},{"key":"R37-20230901","first-page":"1129","article-title":"Low-dose cytosine arabinoside in adult chronic myelomonocytic leukemia","volume":"5","author":"Fenaux","year":"1987","journal-title":"J Clin Oncol"},{"key":"R38-20230901","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.21792","article-title":"Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study","volume":"106","author":"Kantarjian","year":"2006","journal-title":"Cancer"},{"key":"R39-20230901","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","article-title":"Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B","volume":"20","author":"Silverman","year":"2002","journal-title":"J Clin Oncol"},{"key":"R40-20230901","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"key":"R41-20230901","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/cncr.22457","article-title":"Activity of decitabine, a hypomethylating agent, in chronic myelomonocytic leukemia","volume":"109","author":"Aribi","year":"2007","journal-title":"Cancer"},{"key":"R42-20230901","doi-asserted-by":"crossref","first-page":"3824","DOI":"10.1182\/blood-2011-05-352039","article-title":"Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial","volume":"118","author":"Braun","year":"2011","journal-title":"Blood"},{"key":"R43-20230901","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1002\/cncr.25759","article-title":"Activity of azacitidine in chronic myelomonocytic leukemia","volume":"117","author":"Costa","year":"2011","journal-title":"Cancer"},{"key":"R44-20230901","doi-asserted-by":"crossref","first-page":"658","DOI":"10.3109\/10428194.2012.719617","article-title":"High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study","volume":"54","author":"Fianchi","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"R45-20230901","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.leukres.2012.04.024","article-title":"Treatment of chronic myelomonocytic leukemia with 5-azacitidine: a case series and literature review","volume":"36","author":"Thorpe","year":"2012","journal-title":"Leuk Res"},{"key":"R46-20230901","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.leukres.2007.08.004","article-title":"Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML)","volume":"32","author":"Wijermans","year":"2008","journal-title":"Leuk Res"},{"key":"R47-20230901","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.leukres.2013.01.004","article-title":"Predictive factors of response and survival among chronic myelomonocytic leukemia patients treated with azacitidine","volume":"37","author":"Ades","year":"2013","journal-title":"Leuk Res"},{"key":"R48-20230901","doi-asserted-by":"crossref","first-page":"878","DOI":"10.3109\/10428194.2012.730615","article-title":"Treatment of chronic myelomonocytic leukemia with azacitidine","volume":"54","author":"Wong","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"R49-20230901","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1046\/j.1365-2141.2002.03552.x","article-title":"Allogeneic stem cell transplantation of adult chronic myelomonocytic leukaemia. A report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)","volume":"118","author":"Kroger","year":"2002","journal-title":"Br J Haematol"},{"key":"R50-20230901","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.bbmt.2010.09.018","article-title":"Allogeneic hematopoietic cell transplantation for chronic myelomonocytic leukemia: relapse-free survival is determined by karyotype and comorbidities","volume":"17","author":"Eissa","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"R51-20230901","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/ejh.12073","article-title":"Allogeneic stem cell transplantation for chronic myelomonocytic leukemia: a report from the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire","volume":"90","author":"Park","year":"2013","journal-title":"Eur J Haematol"},{"key":"R52-20230901","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.leukres.2015.12.009","article-title":"Impacts of graft-versus-host disease on outcomes after allogeneic hematopoietic stem cell transplantation for chronic myelomonocytic leukemia: a nationwide retrospective study","volume":"41","author":"Itonaga","year":"2016","journal-title":"Leuk Res"},{"key":"R53-20230901","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/bjh.13576","article-title":"Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation","volume":"171","author":"Symeonidis","year":"2015","journal-title":"Br J Haematol"},{"key":"R54-20230901","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1200\/JCO.2012.46.8652","article-title":"Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis","volume":"31","author":"Koreth","year":"2013","journal-title":"J Clin Oncol"},{"key":"R55-20230901","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1182\/blood-2004-01-0338","article-title":"A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome","volume":"104","author":"Cutler","year":"2004","journal-title":"Blood"},{"key":"R56-20230901","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.bbmt.2015.08.031","article-title":"Treatment with hypomethylating agents before allogeneic stem cell transplant improves progression-free survival for patients with chronic myelomonocytic leukemia","volume":"22","author":"Kongtim","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"R57-20230901","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/S1470-2045(15)00038-8","article-title":"Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study","volume":"16","author":"Issa","year":"2015","journal-title":"Lancet Oncol"},{"key":"R58-20230901","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1182\/blood.V124.21.529.529","article-title":"First clinical results of a randomized phase 2 dose\u2013response study of SGI-110, a novel subcutaneous (SC) hypomethylating agent (HMA), in 102 patients with intermediate (Int) or high risk (HR) myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML)","volume":"124","author":"Garcia-Manero","year":"2014","journal-title":"Blood"},{"key":"R59-20230901","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.7754\/Clin.Lab.2015.141240","article-title":"Expressions of CD96 and CD123 in bone marrow cells of patients with myelodysplastic syndromes","volume":"61","author":"Zhang","year":"2015","journal-title":"Clin Lab"},{"key":"R60-20230901","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1038\/sj.leu.2401903","article-title":"The interleukin-3 receptor alpha chain is a unique marker for human acute myelogenous leukemia stem cells","volume":"14","author":"Jordan","year":"2000","journal-title":"Leukemia"},{"key":"R61-20230901","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1038\/leu.2013.355","article-title":"Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents","volume":"28","author":"Yang","year":"2014","journal-title":"Leukemia"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00001622-201701000-00014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T02:36:28Z","timestamp":1693535788000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00001622-201701000-00014"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":61,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/cco.0000000000000337","relation":{},"ISSN":["1040-8746","1531-703X"],"issn-type":[{"value":"1040-8746","type":"print"},{"value":"1531-703X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1]]}}}